SCHEMBL9014227

SCHEMBL9014227

OC[C@H]1O[C@@H](O)[C@H](Oc2ccc(O)cc2)[C@@H](O)[C@@H]1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 4/20 0.66
POLB P06746 2/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
G6PD P11413 1/20 0.46
MAPK1 P28482 1/20 0.46
ADRA1A P35348 1/20 0.46
PTGS2 P35354 1/20 0.46
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA4 P22748 2/20 0.44
CA5A P35218 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA3 P07451 1/20 0.44
CA13 Q8N1Q1 1/20 0.44
CA14 Q9ULX7 1/20 0.44
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL940139 1.00 TYR (0.66) TYRPOLBKDM4EGAAMAPT
SCHEMBL9013983 1.00 TYR (0.66) TYRPOLBKDM4EGAAMAPT
SCHEMBL7690243 1.00 TYR (0.66) TYRPOLBKDM4EGAAMAPT
SCHEMBL18920263 1.00 TYR (0.66) TYRPOLBKDM4EGAAMAPT
SCHEMBL435260 1.00 TYR (0.66) TYRPOLBKDM4EGAAMAPT
SCHEMBL9014038 0.87 TYR (0.51) TYRPOLBKDM4EGAAMAPT
SCHEMBL291103 0.86 TYR (0.49) TYR
SCHEMBL6582069 0.86 TYR (0.49) TYRPOLB
SCHEMBL21045067 0.86 SLC5A2 (0.49) TYRCA12CA9
SCHEMBL869387 0.86 TYR (0.49) TYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383897-A1 BIOACTIVE COMPOSITIONS COMPRISING FICUS SERUM FRACTON AND METHODS TO REDUCE THE APPEARANCE OF SKIN HYPERPIGMENTATION ISP INVESTMENTS LLC (US) 2020-12-10 US disclosed
EP-0745719-A2 Use of carbohydrate compounds as auxiliary agents in the dyeing or printing of fibrous materials HOECHST AKTIENGESELLSCHAFT (DE) 1996-12-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383897-A1 BIOACTIVE COMPOSITIONS COMPRISING FICUS SERUM FRACTON AND METHODS TO REDUCE THE APPEARANCE OF SKIN HYPERPIGMENTATION CUTA, FIBP, FGF23 TYR 39/4885POLB 2565/4885KDM4E 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.